On March 3, 2023 Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company") a commercial-stage, cancer prevention medical diagnostics company and majority-owned subsidiary of PAVmed Inc. (Nasdaq: PAVM, PAVMZ), reported that it will host a business update conference call and webcast on Tuesday, March 14, 2023, at 8:30 AM EST (Press release, Lucid Diagnostics, MAR 3, 2023, View Source [SID1234628134]). During the call, Lishan Aklog, M.D., Lucid’s Chairman and Chief Executive Officer, will provide a business update, including an overview of the Company’s operations and growth strategy. In addition, Dennis McGrath, Lucid’s Chief Financial Officer, will discuss the Company’s fourth-quarter 2022 financial results.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The webcast will be available at the investor relations section of the Company’s website at luciddx.com. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 877-550-1858 and international listeners should dial 1-848-488-9160. All listeners should provide the operator with the conference call name "Lucid Diagnostics Business Update Conference Call" to join.

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at luciddx.com.